GE Healthcare

GE Healthcare


Sorry, your search for: did not find any results

Search Suggestions: Make sure your keyword(s) are spelled correctly Try another keyword(s) Try more general keyword(s)

FDA Approval of Viazmyl (Flutemetamol F18 Injection) for Detection of Beta Amyloid

October 28, 2013

On the left side is a negative scan of a brain, on the right is a positive scan of the brain.

GE Healthcare today announced the U.S. Food and Drug Administration (FDA) approval of Vizamyl™ (Flutemetamol F18 injection),a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. 

Vizamyl is an adjunct to other diagnostic evaluations.1 Vizamyl is the only PET imaging tracer for detection of amyloid approved by FDA for visual interpretation of color images rather than black and white assessment, and will be commercially available in 2014.

PRESS CONTACT: Aleisia Gibson ( +1 609 514 6046


Press Images

Press Kit Document Downloads